Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 163-169

  Tsao, Che Kai ^a   Seng, Sonia ^a   Oh, William K ^a   Galsky, Matthew D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cabazitaxel; Castration resistant; Chemotherapy; Prostate cancer

Indexed keywords

CABAZITAXEL; CAPECITABINE; CISPLATIN; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; GEMCITABINE; GLYCOPROTEIN P; MITOXANTRONE; PREDNISONE; TAXANE DERIVATIVE;

ANEMIA; ARTHRALGIA; ASTHENIA; BACKACHE; BINDING AFFINITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEMATURIA; HUMAN; LEUKOPENIA; LIVER METABOLISM; NAUSEA; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

EID: 84860397235     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6566     Document Type: Review

References (16)

1. Yagoda A. Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma. Cancer. 1973;32:1131-1140.
2. Yagoda A. Cytotoxic agents in prostate cancer: an enigma. Semin Urol. 1983;1:311-321.
3. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitox-antrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351:1502-1512.
5. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews Cancer. 2004;4:253-265.
6. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clinical Cancer Research. 2009;15:723-730.
7. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol. 1999;39:361-398.
8. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Brit J Pharmacol. 2003;138:1367-1375.
9. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723-730.
10. Andrew D, Goetz LJD, Rowinsky EK, et al. Phase I and Pharmacokinetic Study of RPR116258A, a Novel Taxane Derivative, Administered Intravenously over 1 Hour Every 3 Weeks. In: Proc Am Soc Clin Oncol. 2001.
11. Yoo GH, Kafri Z, Ensley JF, et al. XRP6258-induced gene expression patterns in head and neck cancer carcinoma. Laryngoscope. 2010;120:1114-1119.
12. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19:1547-1552.
13. Villanueva C, Awada A, Campone M, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study. Eur J Cancer. 2011.
14. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376: 1147-1154.
15. JEVTANA (Cabazitaxel): Prescribing Information. 2010. (Accessed March, 15th 2011, at http://products.sanof-aventis.us/jevtana/jevtana.html).
16. Current Trials: Cabazitaxel. (Accessed March, 15th, 2011, at http://clinicaltrials.gov/ct2/results?term=cabazitaxel).